Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF)

Key Points

• Unusually large options activity: investors bought 2,705 call options, about a 288% increase versus the typical daily call volume of 698.
• Shares slid $1.01 to $1.93 on very heavy trading (6,047,238 shares vs. an average of 1,045,943), leaving a market cap of about $129.9 million and a 12‑month range of $1.85–$4.99.
• Analyst views are mixed but skew positive on average: MarketBeat shows a “Moderate Buy” consensus with a $11.13 average price target, while individual notes range from Weiss’s “sell (d-)” to Noble Financial’s “outperform” with a $12 target.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 2,705 call options on the company. This is an increase of approximately 288% compared to the typical daily volume of 698 call options.

Cardiff Oncology Price Performance

Shares of CRDF traded down $1.01 during midday trading on Tuesday, hitting $1.93. The stock had a trading volume of 6,047,238 shares, compared to its average volume of 1,045,943. The firm has a market cap of $129.94 million, a price-to-earnings ratio of -2.44 and a beta of 1.40. The company has a 50 day simple moving average of $2.61 and a two-hundred day simple moving average of $2.53. Cardiff Oncology has a twelve month low of $1.85 and a twelve month high of $4.99.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.12 million. Analysts forecast that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Capital Advisors Wealth Management LLC purchased a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $30,000. Jeppson Wealth Management LLC purchased a new position in Cardiff Oncology in the third quarter worth $25,000. Brooklyn Investment Group bought a new position in Cardiff Oncology in the 3rd quarter valued at $26,000. Integrity Alliance LLC. purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $41,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $43,000. Institutional investors own 16.29% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Noble Financial began coverage on Cardiff Oncology in a report on Monday, January 5th. They issued an "outperform" rating and a $12.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.13.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff's pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.